The global nephroblastoma therapeutics industry is on the cusp of significant expansion, with projections indicating a remarkable increase from USD 2.12 billion in 2023 to USD 5.44 billion by 2033. This growth trajectory, representing a compound annual growth rate (CAGR) of 9.88%, underscores the burgeoning demand and advancements in the treatment of nephroblastoma, commonly known …